상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Inhibition of osteoclastogenesis by thioredoxin-interacting protein-derived peptide (TN13)

Authors 

Mi Jeong KimWon Sam KimJae-Eun ByunJung Ha ChoiSuk Ran YoonIn Pyo ChoiHaiyoung Jung

Publisher 

MDPI

Issue Date 

2019

Citation 

Journal of Clinical Medicine

Keywords 

osteoporosisosteoclastosteoclastogenesisp38 MAPKTAT-TN13ovariectomy

Abstract 

Overactivated osteoclasts lead to many bone diseases, including osteoporosis and rheumatoid arthritis. The p38 MAPK (p38) is an essential regulator of the receptor activator of nuclear factor- B ligand (RANKL)-mediated osteoclastogenesis and bone loss. We previously reported TAT conjugated thioredoxin-interacting protein-derived peptide (TAT-TN13) as an inhibitor of p38 in hematopoietic stem cells (HSCs). Here, we examined the role of TAT-TN13 in the differentiation and function of osteoclasts. TAT-TN13 significantly suppressed RANKL-mediated differentiation of RAW 264.7 cells and bone marrow macrophages (BMMs) into osteoclasts. TAT-TN13 also inhibited the RANKL-induced activation of NF- B and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), leading to the decreased expression of osteoclast-specific genes, including tartrate-resistant acid phosphatase (TRAP) and Cathepsin K. Additionally, TAT-TN13 treatment protected bone loss in ovariectomized (OVX) mice. Taken together, these results suggest that TAT-TN13 inhibits osteoclast differentiation by regulating the p38 and NF- B signaling pathway; thus, it may be a useful agent for preventing or treating osteoporosis.

URI 

https://doi.org/10.3390/jcm8040431

ISSN 

2077-0383

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-07-10


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)